Atalanta Sosnoff Capital Boosted Vertex Pharmaceuticals (VRTX) Stake; Cairn Energy plc (LON:CNE) Had 15 Bullish Analysts

Atalanta Sosnoff Capital Llc increased Vertex Pharmaceuticals Inc (VRTX) stake by 35.24% reported in 2017Q3 SEC filing. Atalanta Sosnoff Capital Llc acquired 101,517 shares as Vertex Pharmaceuticals Inc (VRTX)’s stock rose 33.61%. The Atalanta Sosnoff Capital Llc holds 389,601 shares with $59.24M value, up from 288,084 last quarter. Vertex Pharmaceuticals Inc now has $44.60 billion valuation. The stock increased 0.97% or $1.69 during the last trading session, reaching $175.66. About 2.46 million shares traded or 38.73% up from the average. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since March 19, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Among 26 analysts covering Cairn Energy PLC (LON:CNE), 15 have Buy rating, 0 Sell and 11 Hold. Therefore 58% are positive. Cairn Energy PLC has GBX 340 highest and GBX 130 lowest target. GBX 229.14’s average target is 13.44% above currents GBX 202 stock price. Cairn Energy PLC had 214 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Overweight” rating given on Wednesday, January 24 by JP Morgan. On Monday, February 8 the stock rating was maintained by Davy Research with “Neutral”. The stock of Cairn Energy plc (LON:CNE) has “Buy” rating given on Tuesday, February 7 by Deutsche Bank. Tudor Pickering maintained Cairn Energy plc (LON:CNE) rating on Wednesday, January 20. Tudor Pickering has “Accumulate” rating and GBX 240 target. Numis Securities maintained it with “Buy” rating and GBX 270 target in Thursday, February 1 report. On Tuesday, May 31 the stock rating was downgraded by Deutsche Bank to “Hold”. BMO Capital Markets maintained Cairn Energy plc (LON:CNE) rating on Monday, February 8. BMO Capital Markets has “Market Perform” rating and GBX 140 target. The rating was upgraded by Societe Generale on Friday, July 24 to “Hold”. The firm has “Reduce” rating by AlphaValue given on Thursday, December 24. Deutsche Bank maintained Cairn Energy plc (LON:CNE) on Friday, July 15 with “Hold” rating. See Cairn Energy plc (LON:CNE) latest ratings:

14/03/2018 Broker: Barclays Capital Rating: Overweight Maintain
14/03/2018 Broker: JP Morgan Rating: Overweight Old Target: GBX 241.00 New Target: GBX 241.00 Maintain
14/03/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 240.00 New Target: GBX 230.00 Maintain
13/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 260.00 New Target: GBX 260.00 Maintain
12/03/2018 Broker: Morgan Stanley Rating: Overweight Old Target: GBX 270.00 New Target: GBX 300.00 Upgrade
27/02/2018 Broker: Credit Suisse Rating: Outperform Old Target: GBX 260.00 New Target: GBX 260.00 Maintain
20/02/2018 Broker: Deutsche Bank Rating: Hold Maintain
20/02/2018 Broker: Barclays Capital Rating: Overweight Maintain
01/02/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 270.00 New Target: GBX 270.00 Maintain
31/01/2018 Broker: Barclays Capital Rating: Overweight Old Target: GBX 265.00 New Target: GBX 280.00 Maintain

The stock decreased 1.46% or GBX 3 during the last trading session, reaching GBX 202. About 98,593 shares traded. Cairn Energy plc (LON:CNE) has 0.00% since March 19, 2017 and is . It has underperformed by 16.70% the S&P500.

Cairn Energy PLC operates as an oil and gas exploration, development, and production company. The company has market cap of 1.17 billion GBP. It primarily holds interests in Senegal, the United Kingdom, Norway, Malta, Morocco, and the Republic of Ireland. It has a 4.54 P/E ratio. The firm also holds interests in two licenses covering an area of 1,100 km located in the Sureste basin, Gulf of Mexico.

Since October 2, 2017, it had 0 insider purchases, and 46 selling transactions for $123.56 million activity. SMITH IAN F also sold $10.88M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. Chodakewitz Jeffrey sold 60,000 shares worth $8.70M. Arbuckle Stuart A sold $675,750 worth of stock or 4,250 shares. The insider MCGLYNN MARGARET G sold 20,000 shares worth $3.25 million. ALTSHULER DAVID had sold 1,796 shares worth $298,330 on Friday, February 2. 2,330 shares were sold by Parini Michael, worth $379,976. Shares for $5.80 million were sold by Sachdev Amit on Tuesday, October 31.

Investors sentiment decreased to 1.34 in Q3 2017. Its down 0.28, from 1.62 in 2017Q2. It is negative, as 32 investors sold VRTX shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Manufacturers Life Insurance Communications The owns 0.05% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 279,767 shares. Morgan Stanley invested in 0.04% or 834,257 shares. Amp Limited owns 130,142 shares. Etrade Capital Mngmt Ltd Liability Corporation stated it has 9,303 shares or 0.05% of all its holdings. Jane Street Group Limited Liability has 12,255 shares. Symphony Asset Lc, California-based fund reported 4,889 shares. Texas Permanent School Fund owns 69,870 shares or 0.14% of their US portfolio. Cookson Peirce And stated it has 7,290 shares or 0.11% of all its holdings. Ls Inv Advsr Limited Company invested in 0.06% or 6,900 shares. Sumitomo Mitsui Asset Mgmt invested 0.04% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Lenox Wealth Mgmt Inc holds 0.01% or 222 shares. Moreover, Sg Americas Secs Ltd Liability Corp has 0.02% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 15,282 shares. State Of Tennessee Treasury Department holds 173,598 shares. Thompson Davis And Com reported 134 shares or 0.04% of all its holdings. Fred Alger Mgmt Incorporated holds 1.23% or 1.73M shares in its portfolio.

Atalanta Sosnoff Capital Llc decreased Pepsico Inc (NYSE:PEP) stake by 8,353 shares to 283,403 valued at $31.58M in 2017Q3. It also reduced Marsh & Mclennan Cos Inc (NYSE:MMC) stake by 4,325 shares and now owns 290,318 shares. General Motors Co (NYSE:GM) was reduced too.

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals had 99 analyst reports since July 31, 2015 according to SRatingsIntel. Vetr upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Monday, August 17. Vetr has “Hold” rating and $142.57 target. The stock has “Buy” rating by Leerink Swann on Tuesday, September 26. On Tuesday, September 1 the stock rating was upgraded by Vetr to “Buy”. Barclays Capital upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Thursday, February 1. Barclays Capital has “Buy” rating and $200.0 target. Maxim Group maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Wednesday, January 31 with “Buy” rating. The firm has “Buy” rating given on Thursday, October 26 by Needham. BMO Capital Markets maintained it with “Buy” rating and $18000 target in Tuesday, July 18 report. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Nomura on Wednesday, September 16. Stifel Nicolaus maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Friday, September 29. Stifel Nicolaus has “Buy” rating and $182.0 target. Oppenheimer upgraded it to “Buy” rating and $190.0 target in Thursday, February 1 report.